News
CADL
5.82
-12.61%
-0.84
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Seeking Alpha · 9h ago
Weekly Report: what happened at CADL last week (0408-0412)?
Weekly Report · 18h ago
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
NASDAQ · 3d ago
LPCN, ADIL and CADL among pre-market losers
Seeking Alpha · 3d ago
GLYC, APLD and AUTL are among after hour movers
Seeking Alpha · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Rent the Runway, Lumen Technologies, Enliven Therapeutics
The Dow Jones Industrial Average was up 0.02% on Thursday. The benchmark S&P 500 and the Dow were muted as long-dated Treasury yields remained elevated. Rent the Runway, Lumen Technologies, Enliven Therapeutics were among the top stocks on the NYSE.
Reuters · 4d ago
Health Care Sector Update for 04/11/2024: UNH, ELYM, CADL
NASDAQ · 4d ago
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Fastenal shares dipped 6.7% to $69.73 on Thursday. The company reported worse-than-expected first-quarter financial results. Rallybio Corporation shares climbed 89.6% after company announced a collaboration with Johnson & Johnson. Rent the Runway, Inc. Shares jumped 74.5% after the company reported mixed fourth-quarter results.
Benzinga · 4d ago
NKTR, VERU and EGIO among mid-day movers
U.S. Economy NKTR, VERU and EGIO among mid-day movers. Rent the Runway (RENT) and Rallybio Corp are among the gainers. Aptevo Therapeutics (NA) is one of the biggest losers.
Seeking Alpha · 4d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Rallybio (NASDAQ:RLYB) shares moved upwards by 70.5% to $2.78 during Thursday's regular session. Nektar Therapeutics and Alpine Immune Sciences were the biggest gainers during the session. Akanda and Candel Therapeutic were among the losers.
Benzinga · 4d ago
BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
The benchmark S&P 500 and the Nasdaq gained on Thursday. Producer prices data soothed investor jitters about sticky inflation. The Dow Jones Industrial Average was down 0.36% in the morning. Constellation Brands, Nike, Rocket Lab and Domino's Pizza are among the stocks on the move.
Reuters · 4d ago
What's Going On With Candel Therapeutics Stock?
Candel Therapeutics, Inc. Shares are trading higher after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. Candel shares are moving on heavy trading volume following the company's announcement. The company does not pay a dividend.
Benzinga · 4d ago
Candel Therapeutics' CAN-2409 For Pancreatic Cancer Gets FDA Orphan Drug Designation; Stock Up
NASDAQ · 4d ago
BUZZ-Candel Therapeutics jumps on orphan drug tag for lead cancer therapy
Shares of Candel Therapeutics climb 23.5% to $6.3 premarket. U.S. FDA has granted "orphan drug" designation for lead cancer therapy. Candel's lead investigational therapy, CAN-2409, for the treatment of a type of pancreatic cancer.
Reuters · 4d ago
SHARES OF CANDEL THERAPEUTICS UP 27% ON FDA'S ORPHAN DRUG TAG FOR LEAD CANCER THERAPY
Reuters · 4d ago
Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation
Shares of Candel Therapeutics jumped nearly 30% in premarket trading. Candel said the FDA granted orphan-drug designation to CAN-2409 for the treatment of pancreatic cancer. The company last year won FDA fast-track designation for the lead product candidate.
Dow Jones · 4d ago
Candel Therapeutics Gains Orphan Drug Status for Cancer Treatment
TipRanks · 4d ago
CANDEL THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR CAN-2409 FOR THE TREATMENT OF PANCREATIC CANCER
Reuters · 4d ago
BSGM, WAVE and TCBP among pre-market losers
U.S. Economy BSGM, WAVE and TCBP among pre-market losers. PainReform Ltd (PRFX) and Biosig Technologies (BSGM) lose 15% and 14%. Hexcel Corp. (HXL) names former Spirit AeroSystems head Gentile as new CEO.
Seeking Alpha · 5d ago
AEYE, GSIT and VVPR among mid-day movers
Seeking Alpha · 6d ago
More
Webull provides a variety of real-time CADL stock news. You can receive the latest news about Candel Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CADL
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.